{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:07:46Z","timestamp":1789567666793,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s42000-025-00743-2","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:22:53Z","timestamp":1766125373000},"page":"475-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus"],"prefix":"10.1007","volume":"25","author":[{"given":"Virginia","family":"Markoutsaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Dimakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Sinakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1352","authenticated-orcid":false,"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"743_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14656566.2024.2312239","volume":"25","author":"T Koufakis","year":"2024","unstructured":"Koufakis T, Popovic DS, Papadopoulos C, Giouleme O, Doumas M (2024) Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time! Expert Opin Pharmacother 25:123\u2013126. https:\/\/doi.org\/10.1080\/14656566.2024.2312239","journal-title":"Expert Opin Pharmacother"},{"key":"743_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH (2021) Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int 41:261\u2013270. https:\/\/doi.org\/10.1111\/liv.14669","journal-title":"Liver Int"},{"key":"743_CR3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L (2025) Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 31:S32\u2013S50. https:\/\/doi.org\/10.3350\/cmh.2024.0431","journal-title":"Clin Mol Hepatol"},{"key":"743_CR4","doi-asserted-by":"publisher","first-page":"108811","DOI":"10.1016\/j.pharmthera.2025.108811","volume":"268","author":"K Arvanitakis","year":"2025","unstructured":"Arvanitakis K, Koufakis T, Cholongitas E, Francque S, Germanidis G (2025) Insights into the results of Resmetirom trials: can a thyroid hormone receptor agonist be the holy grail of MASH therapy? Pharmacol Ther 268:108811. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108811","journal-title":"Pharmacol Ther"},{"key":"743_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16603","author":"JS Neves","year":"2025","unstructured":"Neves JS, Vale C, Leite AR, Ferreira JP (2025) Cardiorenal outcomes and mortality with GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: an updated systematic review and meta-analysis. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.16603","journal-title":"Diabetes Obes Metab"},{"key":"743_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01635-6","volume":"17","author":"A Mousavi","year":"2025","unstructured":"Mousavi A, Shojaei S, Soleimani H et al (2025) Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr 17:68. https:\/\/doi.org\/10.1186\/s13098-025-01635-6","journal-title":"Diabetol Metab Syndr"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.eprac.2024.11.017","volume":"31","author":"R Xu","year":"2025","unstructured":"Xu R, Liu B, Zhou X (2025) Comparison of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter protein-2 inhibitors on treating metabolic dysfunction-associated steatotic liver disease or metabolic dysfunction-associated steatohepatitis: systematic review and network meta-analysis of randomised controlled trials. Endocr Pract 31:521\u2013535. https:\/\/doi.org\/10.1016\/j.eprac.2024.11.017","journal-title":"Endocr Pract"},{"key":"743_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/00365513.2023.2241363","volume":"83","author":"A \u00c5sberg","year":"2023","unstructured":"\u00c5sberg A, L\u00f8fblad L, Hov GG, Mikkelsen G (2023) Reference change values of FIB-4. Scand J Clin Lab Invest 83:394\u2013396. https:\/\/doi.org\/10.1080\/00365513.2023.2241363","journal-title":"Scand J Clin Lab Invest"},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"e70003","DOI":"10.1111\/eci.70003","volume":"55","author":"LAM Konings","year":"2025","unstructured":"Konings LAM, Miguela\u00f1ez-Matute L, Boeren AMP et al (2025) Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: a systematic review. Eur J Clin Invest 55:e70003. https:\/\/doi.org\/10.1111\/eci.70003","journal-title":"Eur J Clin Invest"},{"key":"743_CR10","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.dsx.2020.09.030","volume":"14","author":"E Makri","year":"2020","unstructured":"Makri E, Kita M, Goulas A et al (2020) Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr 14:1913\u20131919. https:\/\/doi.org\/10.1016\/j.dsx.2020.09.030","journal-title":"Diabetes Metab Syndr"},{"key":"743_CR11","doi-asserted-by":"publisher","first-page":"100666","DOI":"10.1016\/j.gastha.2025.100666","volume":"4","author":"SO Gbadamosi","year":"2025","unstructured":"Gbadamosi SO, Nagelhout E, Sienko D et al (2025) Association of index and changes in Fibrosis-4 score with outcomes in metabolic dysfunction-associated steatohepatitis. Gastro Hep Adv 4:100666. https:\/\/doi.org\/10.1016\/j.gastha.2025.100666","journal-title":"Gastro Hep Adv"},{"key":"743_CR12","doi-asserted-by":"publisher","first-page":"101153","DOI":"10.1016\/j.lanepe.2024.101153","volume":"48","author":"J Boeckmans","year":"2024","unstructured":"Boeckmans J, Prochaska JH, Gieswinkel A et al (2024) Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study. Lancet Reg Health Eur 48:101153. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101153","journal-title":"Lancet Reg Health Eur"},{"key":"743_CR13","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.jhepr.2021.100293","volume":"3","author":"D Mansour","year":"2021","unstructured":"Mansour D, Grapes A, Herscovitz M et al (2021) Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep 3:100293. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100293","journal-title":"JHEP Rep"},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"12198","DOI":"10.1038\/s41598-024-62549-3","volume":"14","author":"D Ouzan","year":"2024","unstructured":"Ouzan D, Penaranda G, Jlaiel M et al (2024) Using the FIB-4, automatically calculated, followed by the ELF test in second line to screen primary care patients for liver disease. Sci Rep 14:12198. https:\/\/doi.org\/10.1038\/s41598-024-62549-3","journal-title":"Sci Rep"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-025-00743-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:31:39Z","timestamp":1789565499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-025-00743-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1007\/s42000-025-00743-2","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Informed consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the Medical School of Aristotle University of Thessaloniki (approval number 3\/14\u20131-2025), Greece.","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ES\u00a0has received honoraria for lectures and for serving on advisory boards from Novo Nordisk\u00a0and has participated in sponsored studies by Boehringer Ingelheim\u00a0and Novo Nordisk.\u00a0KK has received honoraria for lectures\/serving on advisory boards and research support from Astra Zeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD and Novo Nordisk; KK\u00a0is an Associate Editor of Hormones and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. TK has received honoraria for lectures from AstraZeneca, Sanofi, Boehringer Ingelheim, Pharmaserve Lilly, ELPEN, Menarini, and Novo Nordisk, for serving on advisory boards from Novo Nordisk, Roche, Sanofi, and Boehringer Ingelheim and has participated in sponsored studies by Eli-Lilly, AstraZeneca, and Novo Nordisk. The other authors declare that no conflicts of interest or financial relationships relevant to this article exist.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}